Compare State Street SPDR S&P Biotech ETF (XBI) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Xylem, Inc. — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.35, while Xylem, Inc. trades at $121.4 (market cap $28.76B). The key difference: Xylem, Inc. pays a 1.4% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Xylem, Inc. nearer its low. Which is the better fit depends on your goals.
| XBI | XYL | |
|---|---|---|
Sector | Broad Market / Factor | Industrials |
52-Week High | $164.28 | $152.95 |
52-Week Low | $86.92 | $106.34 |
Market Cap | — | $28.76B |
Enterprise Value | — | $30.54B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Xylem (XYL) trades at $121.87, up 0.56% today, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The company's fundamentals show robust revenue growth, expanding margins, and healthy cash flow, supported by strategic acquisitions like Cornell Pump and Roper Pump to bolster its industrial water technology presence. Analyst consensus is mixed but leans positive, with a $150.43 price target implying significant upside.
Outlook remains favorable due to secular demand in water infrastructure and AI-driven data centers, though risks include execution on acquisitions and economic sensitivity. The stock offers growth potential from margin expansion and digital water solutions, but investors should monitor integration challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
